Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine-SR in Multiple Sclerosis
NCT00053417Phase 2Completed
- Sponsor
- Acorda Therapeutics
- Start
- Feb 2003
- Primary completion
- Dec 2003
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of dalfampridine in multiple sclerosis (MS) (4 arms), sponsored by Acorda Therapeutics. Primary endpoint: Median Percent Change From Baseline in Average Walking Speed on Timed 25-Foot Walk Test at 12 weeks. Started Feb 2003; status: completed.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00053417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053417.